CD20-PD1 Binding Molecules for Targeted Autoimmune Suppression

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for autoimmune diseases, such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and multiple sclerosis (MS), have limited success and often come with severe side effects, lacking a long-term cure.

Innovation Solution

Development of CD20-PD1 binding molecules comprising CD20 targeting moieties and PD1 agonist moieties, which can modulate the immune response to treat autoimmune diseases by repressing autoreactive T and B cells.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If general immunosuppressive drug therapies (cyclosporin A, FK506, rapamycin) are used to treat autoimmune diseases, then immune suppression is achieved, but serious side effects occur including nephrotoxicity, increased predisposition to infectious diseases, and enhanced incidence of neoplasia

Engineering Contradiction:

Improveimmune suppression effectivenessVSAvoidnephrotoxicity, infectious disease predisposition, neoplasia incidence

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies local quality by directing immune suppression specifically to autoreactive T and B cells through dual targeting of CD20 (on B cells) and PD-1 (on T cells), rather than applying general immunosuppression to all immune cells. This localized approach achieves immune suppression effectiveness while minimizing broad immunosuppressive side effects.

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent uses an engineered binding molecule as an intermediary that simultaneously binds to CD20 and PD-1, mediating the suppression of autoreactive immune cells. This intermediary approach allows precise control over which cells are suppressed, avoiding the harmful effects of non-specific immunosuppressive drugs.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Ease of operation

If existing treatments (corticosteroids, modified beta interferon) are used to alleviate autoimmune disease symptoms, then some symptom relief is achieved, but long-term cure is not possible and serious side effects occur

Engineering Contradiction:

Improvesymptom alleviationVSAvoidlong-term curative effect

Core Design Contradiction:

Ease of operationVSDuration of action of stationary object

Solution Approach 1:

The patent applies preliminary action by using the engineered CD20-PD-1 binding molecule to suppress autoreactive T and B cells before they can cause significant tissue damage and disease progression. By acting early and specifically on the pathogenic cells, the treatment aims to prevent disease recurrence and achieve long-term remission rather than merely alleviating symptoms.

Inventive Principle:

Principle #10Preliminary action

3Reliability

If CD20-PD1 binding molecules are designed to target both CD20 and PD-1, then autoreactive T and B cell suppression is enhanced, but molecule complexity increases

Engineering Contradiction:

Improveautoreactive cell suppression effectivenessVSAvoidbinding molecule structure

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent merges two separate targeting functions (CD20 binding and PD-1 binding) into a single engineered molecule. This combining approach allows simultaneous targeting of both CD20 on B cells and PD-1 on T cells, enhancing suppression effectiveness while maintaining a unified molecular structure that can be produced and administered as a single therapeutic agent.

Inventive Principle:

Principle #5Merging (Combining)

Data Source

PatentUS12559576B2CD20-PD1 binding molecules and methods of use thereof

Publication Date: 2026.02.24 REGENERON PHARMACEUTICALS INC

AI summary

The present disclosure relates to molecules capable of binding to both CD20 and PD1, as well as pharmaceutical compositions comprising such molecules and methods of use thereof.